Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

NCT07524322 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Ovarian Cancer
Endometrial Cancer
PIK3CA Mutation
HER2- Negative Breast Cancer
Advanced Breast Cancer
Unresectable Solid Tumor
Hormone Receptor Positive Tumor
Cervical Cancer

Interventions

DRUG: RGT-490

Sponsor

Regor Pharmaceuticals Inc.